Biotech startups and established pharmaceutical companies are building a diverse portfolio of therapies, diagnostics, and monitoring tools designed to address Alzheimer’s disease through multiple mechanisms. The most advanced approaches target amyloid-beta plaques and tau protein tangles—the two hallmark proteins that accumulate in the Alzheimer’s brain—while newer startups are exploring neuroinflammation, vascular dysfunction, and metabolic pathways as parallel routes to disease modification. In January 2023, Eli Lilly and Biogen’s lecanemab (Leqembi) became the first monoclonal antibody to show meaningful cognitive slowing in early symptomatic disease, reducing decline by 27% over 18 months in a 1,736-patient trial, which opened the door for dozens of follow-on programs targeting amyloid at different stages of accumulation.
Beyond drugs, the startup landscape is equally active in diagnostics, preventive approaches, and companion tools that enable earlier detection and more precise patient selection. Blood-based biomarker tests—which measure phosphorylated tau variants, amyloid ratios, and neurofilament light—are moving out of research labs into clinical validation, reducing the need for expensive PET imaging. Companies like C2N Diagnostics (acquired by Eli Lilly), Quanterix, and Alzheon are racing to make these tests accessible and affordable, recognizing that early intervention window may be only 5–10 years before symptom onset.
Table of Contents
- What Types of Therapies Are Biotech Startups Developing?
- How Are Blood Biomarker Tests Changing Alzheimer’s Diagnosis?
- Are Startups Building Tools for Prevention or Just Treatment?
- How Is AI Being Used to Accelerate Drug Discovery?
- The Blood-Brain Barrier Remains the Central Challenge
- Combination Therapies and the Amyloid-Centric Limitation
- Companion Diagnostics and Patient Selection in Clinical Trials
- Frequently Asked Questions
What Types of Therapies Are Biotech Startups Developing?
Biotech companies are pursuing at least five distinct therapeutic approaches, each targeting a different piece of the Alzheimer’s puzzle. Monoclonal antibodies that bind and clear amyloid (aducanumab, lecanemab, donanemab) represent the furthest along in the clinical pipeline, though efficacy remains modest and amyloid reduction does not always translate to cognitive benefit in symptomatic patients. Tau-targeting therapies from companies like Eli Lilly (remternetug), Roche, and others aim to prevent tau tangles from forming or spreading; these are earlier in development but represent a shift toward combination strategies, since amyloid alone may be insufficient for meaningful cognitive preservation. Neuroinflammation-targeting startups are taking a different angle, using anti-inflammatory molecules or microglial modulators to reduce the chronic brain inflammation that fuels neurodegeneration.
A smaller company like Eisai is studying molecular glue degraders and neuroprotective agents, while academic spinouts are exploring whether dampening neuroinflammation alone—without addressing amyloid—can slow decline. The limitation here is that clinical data are still sparse; the field is betting on mechanism, not yet on proof. Metabolic and vascular approaches round out the landscape. Startups are investigating whether improving mitochondrial function, enhancing vascular perfusion, or modulating metabolic pathways (AMPK activation, NAD+ repletion) can slow neurodegeneration, especially in populations with comorbid diabetes or cardiovascular disease. These programs typically move slower through the clinic because the connection between metabolic dysfunction and tau/amyloid is less direct, but several show promise in animal models.
How Are Blood Biomarker Tests Changing Alzheimer’s Diagnosis?
Phosphorylated tau variants measured in blood plasma—particularly phospho-tau181 and phospho-tau217—have emerged as the most specific diagnostic markers for Alzheimer’s pathology, with sensitivity and specificity exceeding 90% in some studies when compared to amyloid and tau PET. C2N Diagnostics developed the Plasma Phosphorylated-Tau217 test, which correlates strongly with brain pathology even years before symptom onset; after Eli Lilly acquired the company, the test was rebranded and is now offered through clinical reference laboratories. Quanterix and other biotech firms have also commercialized plasma phospho-tau assays, with turnaround times of 1–2 weeks and costs in the $500–$1,500 range (insurance coverage is still variable).
The major advantage is accessibility: a blood draw costs far less and requires no specialized facility compared to amyloid or tau PET imaging ($3,000–$5,000), which is unavailable at most primary care clinics. However, a critical limitation is that positive biomarkers do not predict whether an individual will develop symptoms or decline cognitively over any given timeframe; some cognitively normal people have amyloid and tau in their brain and remain asymptomatic for decades, while others decline rapidly. This ambiguity is why biomarker companies are now layering in machine learning models and longitudinal data to estimate individual risk, but the predictive power remains imperfect.
Are Startups Building Tools for Prevention or Just Treatment?
A small but growing sector of biotech companies is positioning themselves for prevention—identifying cognitively normal people with amyloid and tau pathology and attempting to slow progression before symptoms appear. The Dominantly Inherited Alzheimer Network (DIAN) trial and the AHEAD trial both tested this hypothesis in at-risk populations and in cognitively normal individuals with biomarker evidence of early pathology. Eli Lilly’s donanemab is being studied in the EARLY trial (cognitively unimpaired amyloid-positive adults), while Eli Lilly, Roche, and others are enrolling into prevention cohorts.
The comparison between prevention and symptomatic-stage treatment is stark: slowing decline by 35% in a cognitively normal person means preserving years of healthy life, whereas the same 35% slowdown in someone already experiencing cognitive decline prevents further deterioration but does not restore lost function. Startups and larger companies both recognize this, which is why there is intense investment in blood biomarker accessibility and risk prediction—if you cannot identify the at-risk population before symptoms, you cannot treat them preventively. However, a major challenge is that most primary care physicians do not yet screen for amyloid, and there is no consensus on when or whom to treat in the cognitively normal stage, which limits commercial appeal for startups focused solely on prevention.
How Is AI Being Used to Accelerate Drug Discovery?
Artificial intelligence companies and biotech startups are applying machine learning to predict which molecular compounds will bind amyloid or tau, which will cross the blood-brain barrier, and which will have acceptable safety profiles, dramatically shortening the time from target identification to lead compound. Companies like Atomwise, DeepMind (via parent Alphabet), and Recursion Pharmaceuticals have used AI to screen millions of compounds in silico, identifying leads that would take medicinal chemists months to synthesize and test. In Alzheimer’s specifically, some startups are using AI to predict which patients will respond to amyloid-targeting antibodies based on their genetic profile, biomarker levels, and imaging features.
The tradeoff is real: AI accelerates the computational chemistry phase, but it does not replace the need for expensive animal testing, IND (Investigational New Drug) applications, or human trials. A startup using AI to find a novel tau binder may save 6–12 months in compound optimization, but the Phase 2 trial in humans still requires 2–3 years and $50–$150 million. Additionally, most AI models are trained on historical data sets that may miss novel mechanisms or off-target effects, so early-stage startups relying heavily on AI predictions still encounter clinical surprises. The advantage is cost-savings in the early discovery phase and faster iteration on scaffolds, not a shortcut to proven efficacy.
The Blood-Brain Barrier Remains the Central Challenge
All systemically administered Alzheimer’s drugs must cross the blood-brain barrier (BBB)—a highly selective membrane that blocks most large molecules and even some small molecules. Monoclonal antibodies like lecanemab are large (around 150 kDa) and cross the BBB poorly, which is why some researchers question whether peripheral amyloid clearance, not brain clearance, accounts for the modest cognitive benefit. Startups pursuing smaller molecules (peptides, small-molecule inhibitors, antisense oligonucleotides) aim to cross the BBB more efficiently, but this narrowly constrains chemical space and reduces the number of druggable targets.
Another strategy is to leverage receptor-mediated transport systems (transferrin receptor, LDL receptor variants) or use nanoparticles and exosomes as delivery vehicles to ferry therapeutics across the BBB. Several startups are developing these technologies, but clinical translation is still early; most programs are in preclinical or Phase 1 stages. The practical limitation is that improved BBB penetration often comes at a cost: higher manufacturing complexity, shorter in vivo half-life, or increased off-target binding. One example is ionis’ antisense therapy targeting APOE4 (the strongest genetic risk factor for late-onset Alzheimer’s), which showed neuroinflammation reduction in a Phase 2 trial but required intrathecal delivery (spinal tap injection) because the antisense oligonucleotide does not cross the BBB systemically, limiting its adoption to specialized neurology centers.
Combination Therapies and the Amyloid-Centric Limitation
As evidence accumulates that single-target therapies provide modest cognitive benefit, biotech companies are shifting toward combination approaches that address amyloid, tau, and neuroinflammation simultaneously. Eli Lilly is testing combinations of its amyloid-targeting antibody with tau-targeting compounds in preclinical models, and several smaller startups are designing two-in-one molecules that bind both amyloid and tau or both amyloid and neuroinflammatory targets. The hypothesis is that simultaneous attack on multiple pathways will produce synergistic slowing of decline rather than additive benefit.
However, combining two or three drugs exponentially increases the complexity and cost of clinical development. Each added agent requires separate Phase 2 dose-finding studies, and interaction studies between compounds add years and tens of millions of dollars. One startup example is Alzheon, which is investigating combination therapy with an amyloid binder and an anti-inflammatory, but the development timeline has extended beyond initial projections due to manufacturing and regulatory hurdles. The risk for investors is that the additive cost may outweigh the marginal cognitive gain over single-agent therapy, especially if the patient population willing to enroll in longer, more burdensome trials shrinks.
Companion Diagnostics and Patient Selection in Clinical Trials
Biotech companies increasingly recognize that one-size-fits-all dosing and enrollment criteria do not work for disease-modifying Alzheimer’s therapies. Lecanemab is most effective in people with early cognitive decline (mild cognitive impairment or mild dementia) and confirmed amyloid pathology; administering it to amyloid-negative individuals is ineffective and exposes them to infusion-related amyloid angiopathy (ARIA), a potentially severe side effect. Companies like Eli Lilly and Roche are developing or requiring companion diagnostic tests—typically the same phospho-tau or amyloid ratio blood tests—that must be run before enrollment in trials or before prescribing medication.
C2N’s phospho-tau217 blood test has become a de facto companion diagnostic for anti-amyloid monoclonal antibodies; clinical trial sites now use it to screen and enrich for amyloid-positive participants, reducing screen failures and improving statistical power. The practical benefit is that trials move faster and drug developers can focus resources on the population most likely to benefit. A limitation is that patients without amyloid biomarker access are excluded from trials, potentially enriching for healthcare systems in developed countries and potentially biasing trial populations. Additionally, the cost and time required to run biomarker tests before enrollment can slow recruitment in smaller trial sites, which is why some startups are developing point-of-care or rapid-turnaround biomarker assays (results in hours or days) to reduce enrollment friction.
Frequently Asked Questions
Is there a cure for Alzheimer’s disease yet?
No cure exists. Current and pipeline biotech therapies slow cognitive decline by 25–35% in early symptomatic disease and may delay symptom onset in asymptomatic amyloid-positive individuals, but they do not halt or reverse the disease.
Do I need a blood biomarker test if I have memory concerns?
Blood biomarker tests are useful for confirming Alzheimer’s pathology in cognitively impaired individuals, but a positive biomarker alone in cognitively normal people does not predict whether symptoms will develop. Discuss screening with your neurologist or primary care physician.
How much do amyloid-targeting drugs like lecanemab cost?
Lecanemab (Leqembi) carries a list price of approximately $26,500 per year for IV infusions given every two weeks, though insurance coverage and patient assistance programs vary. Out-of-pocket costs depend on your plan.
Are smaller biotech startups or large pharmaceutical companies more likely to develop the next breakthrough Alzheimer’s drug?
Large companies like Eli Lilly, Roche, and Biogen currently dominate late-stage trials and approvals due to resources, but smaller startups are advancing novel mechanisms in early development. Acquisition by larger firms often accelerates a startup’s progress to clinic.
What is ARIA, and should I be concerned if I take an anti-amyloid drug?
ARIA stands for amyloid-related imaging abnormalities—microhemorrhages or microinfarcts visible on MRI that can occur in 10–35% of people taking amyloid-targeting antibodies. Most are asymptomatic, but symptomatic cases cause headache, confusion, or vision changes and require immediate medical evaluation.
